{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:44Z","timestamp":1789010984886,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether baseline vaginal-microbiota status influences the clinical cure rate and 30-day mycological recurrence of severe VVC after 6-day intravaginal ketoconazole therapy compared with miconazole nitrate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, randomized, positive drug-controlled, multicenter clinical study was conducted from April 2022 to October 2023 across nine hospitals in China. A total of 253 patients diagnosed with severe vulvovaginal candidiasis were enrolled. The study group received ketoconazole suppositories, while the control group received miconazole nitrate vaginal capsules. Vaginal microbiota results were recorded at enrollment, and follow-up assessments were conducted at 10 and 30 days post-treatment to evaluate the relationship between vaginal microbiota and treatment efficacy and recurrence rates.Vaginal microbiota was categorised by Gram-stain microscopy into (i) normal flora (\n                      <jats:italic>Lactobacillus<\/jats:italic>\n                      spp. dominant), (ii) BV-associated abnormal flora (Gram-variable short rods dominant) and (iii) non-BV abnormal flora (other morphotypes).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At enrollment, there were no significant differences between the study and control groups in terms of symptom and sign scores, vaginal dominant bacteria. At the 10-day follow-up, the clinical efficacy rates for patients with normal and abnormal vaginal microbiota were 86.7% and 75.5%, respectively, with a statistically significant difference (P\u00a0=\u00a00.021). In the study group, the clinical efficacy rates for patients with normal flora, BV-associated abnormal flora, and non-BV-associated abnormal flora were 89.2%, 79.2%, and 78.9%, respectively, with no significant difference (P\u00a0=\u00a00.264). In the control group, the clinical efficacy rates for patients with normal flora, BV-associated abnormal-flora, and non-BV-associated abnormal flora were 84.1%, 86.7%, and 63.6%, respectively, with a significant difference (P\u00a0=\u00a00.045).Among the 253 patients, 198 patients who achieved clinical cure and mycological negativity after initial treatment and had mycological follow-up results at 30 days were analyzed. The proportion of mycological positivity at the 30-day follow-up was 14.8% (16\/108) in the study group and 26.7% (24\/90) in the control group, with a statistically significant difference in recurrence rates between the two groups (P\u00a0=\u00a00.039). Among the 126 patients with normal dominant bacteria at enrollment,the proportion of mycological positivity at the 30-day follow-up was 12.3% (8\/65) in the study group and 26.2% (16\/61) in the control group, with a statistically significant difference in recurrence rates (P\u00a0=\u00a00.047).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The vaginal microbiota, particularly the dominant bacteria, may influence treatment efficacy and recurrence rates. In the treatment of severe vulvovaginal candidiasis, ketoconazole suppositories are not inferior to miconazole nitrate vaginal capsules in clinical efficacy and have a lower long-term recurrence rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1638454","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:29:49Z","timestamp":1763965789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of vaginal microbiota on the clinical efficacy and long-term recurrence of ketoconazole suppositories in treating severe vulvovaginal candidiasis: a secondary analysis of a multicentre randomised trial"],"prefix":"10.3389","volume":"15","author":[{"given":"Lan","family":"Mi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158870","article-title":"Highlights regarding host predisposing factors to recurrent vulvovaginal candidiasis: chronic stress and reduced antioxidant capacity","volume":"11","author":"Akimoto-Gunther","year":"2016","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1128\/MMBR.00009-06","article-title":"Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans","volume":"71","author":"Biswas","year":"2007","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B3","first-page":"401","article-title":"Revised guidelines for the diagnosis and treatment of vulvovaginal candidiasis (VVC)","volume":"28","year":"2012","journal-title":"Chin. J. Pract. Gynecology Obstetrics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1625952","article-title":"New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections","volume":"16","author":"De Seta","year":"2025","journal-title":"Front. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115024","DOI":"10.1016\/j.diagmicrobio.2020.115024","article-title":"Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC)","volume":"97","author":"Donders","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/1203475415574970","article-title":"The rise and fall of oral ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J.\u00a0Cutaneous Med. Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4161\/viru.20010","article-title":"Regulation of phenotypic transitions in the fungal pathogen Candida albicans","volume":"3","author":"Huang","year":"2012","journal-title":"Virulence"},{"key":"B8","first-page":"229","article-title":"Features of vaginal bacteria community in women with recurrent vulvovaginal candidiasis","volume":"26","author":"Jian","year":"2015","journal-title":"J. Reprod. Contraception"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079812","article-title":"Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"B10","first-page":"340","article-title":"Study on the efficacy of ketoconazole suppositories in the treatment of severe vulvovaginal candidiasis","volume":"40","author":"Mi","year":"2024","journal-title":"Chin.\u00a0J. Pract. Gynecology Obstetrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080074","article-title":"Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota","volume":"8","author":"O'Hanlon","year":"2013","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1113\/JP271694","article-title":"The vaginal microbiota, host defence and reproductive physiology","volume":"595","author":"Smith","year":"2017","journal-title":"J. Physiol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12010108","article-title":"Bacterial vaginosis and vulvovaginal candidiasis pathophysiologic interrelationship","volume":"12","author":"Sobel","year":"2024","journal-title":"Microorganisms"},{"key":"B14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"New Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/GME.0000000000002263","article-title":"Relationships between the vaginal microbiota and genitourinary syndrome of menopause symptoms in postmenopausal women: the Study of Women's Health Across the Nation","volume":"30","author":"Waetjen","year":"2023","journal-title":"Menopause"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"Morbidity Mortality Weekly Rep. (MMWR) Recommendations Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11046-024-00889-4","article-title":"Three-dose antifungal treatment improves the efficacy for severe vulvovaginal candidiasis","volume":"189","author":"Xiao","year":"2024","journal-title":"Mycopathologia"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1638454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:29:50Z","timestamp":1763965790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1638454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":17,"alternative-id":["10.3389\/fcimb.2025.1638454"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1638454","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"article-number":"1638454"}}